Edwards Lifesciences CORP 8-K filings

Edwards Lifesciences reported strong second quarter 2026 results, exceeding sales growth expectations and raising full-year guidance for key product lines.

Edwards Lifesciences stockholders approved the amendment of the Long-Term Stock Incentive Compensation Program and re-elected all director nominees at the 2026 Annual Meeting.

Edwards Lifesciences announces Theodora Mistras as new CFO, succeeding Scott Ullem, effective May 29, 2026.

Edwards Lifesciences announced robust first-quarter 2026 financial results, exceeding expectations and leading to an upward revision of full-year sales and earnings guidance.

Edwards Lifesciences delivered robust fourth-quarter 2025 results, driven by strong TAVR and TMTT sales, and increased its full-year 2026 financial guidance.

Edwards Lifesciences announced the U.S. District Court blocked its acquisition of JenaValve Technology, leading to a revised, higher full-year 2026 adjusted EPS guidance.

Edwards Lifesciences announced that Chief Financial Officer Scott Ullem will transition from his role by mid-year 2026, with a selection process for a new CFO underway.

Edwards Lifesciences reported strong third-quarter 2025 financial results, driven by double-digit sales growth across all product groups, leading to increased full-year guidance.

Edwards Lifesciences initiated a $500 million accelerated share repurchase agreement, bringing its total 2025 repurchases to over $800 million.

Edwards Lifesciences announced the FTC moved to block its proposed acquisition of JenaValve Technology, leading to revised full-year 2025 adjusted EPS guidance.

Edwards Lifesciences Corporation announced the resignation of Larry L. Wood, Group President of Transcatheter Aortic Valve Replacement and Surgical Structural Heart, effective September 1, 2025, with Daniel J. Lippis appointed to a key leadership role.

Edwards Lifesciences reported robust second-quarter 2025 financial results with double-digit sales growth across all product groups, leading to an upward revision of its full-year sales and adjusted EPS guidance.

Edwards Lifesciences Corporation's stockholders approved amendments to the U.S. and International Employee Stock Purchase Plans (ESPP) and elected directors at the 2025 Annual Meeting.

Edwards Lifesciences announced positive first-quarter 2025 financial results, driven by growth in TAVR and TMTT, and raised its TMTT sales guidance for the year.

Edwards Lifesciences announces better-than-expected Q4 results with 9% sales growth and significant gains in TMTT, while reiterating its 2025 outlook.

Edwards Lifesciences announced a robust third quarter with sales growth driven by its TAVR and TMTT segments, alongside the completion of the Critical Care divestiture.

Edwards Lifesciences has finalized the sale of its Critical Care product group to Becton, Dickinson and Company for $4.2 billion, and announced a $1.5 billion share repurchase authorization.

Edwards Lifesciences announced the acquisition of JenaValve and Endotronix, while also reporting second quarter financial results with strong TMTT growth offset by lower-than-expected TAVR growth.

Edwards Lifesciences has announced its acquisition of Innovalve Bio Medical, an early-stage transcatheter mitral valve replacement company, for approximately $300 million in cash.

Edwards Lifesciences has appointed David T. Feinberg, M.D., a seasoned healthcare executive, to its Board of Directors, effective immediately.

Edwards Lifesciences has announced the retirement of its Principal Accounting Officer, Robert W.A. Sellers, effective July 1, 2024, and the appointment of Andrew M. Dahl as his successor.

Edwards Lifesciences has agreed to sell its Critical Care product group to Becton, Dickinson and Company for $4.2 billion in cash, abandoning its previous plan to spin off the unit.

Edwards Lifesciences successfully held its annual stockholder meeting on May 7, 2024, with all director nominees elected and key proposals approved.

Edwards Lifesciences reported strong first-quarter results, with sales growth of 10% and increased full-year guidance, driven by its transcatheter platforms.

Edwards Lifesciences announced the retirement of its Non-Executive Chairman, Michael A. Mussallem, and the departure of director Martha H. Marsh, both effective at the company's annual meeting on May 7, 2024.

Edwards Lifesciences announced a 14% increase in fourth-quarter sales and a 12% increase in full-year sales, driven by growth across all product groups and the early FDA approval of EVOQUE.